Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study
Background Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) to improve exercise capacity. This post hoc analysis evaluated clinical worsening and PH-ILD exacerbations from the 16-week INCREASE study and change in 6-minute...
Main Authors: | Steven D Nathan, Hilary M DuBrock, Victor F Tapson, Aaron B Waxman, Karim El-Kersh, Jason Weatherald, Eric Shen, Chunqin Deng, Steven J Cassady, Rahul G Argula, Franz P Rischard, James Tarver, Deborah J Levine, Manisit Das |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-03-01
|
Series: | BMJ Open Respiratory Research |
Online Access: | https://bmjopenrespres.bmj.com/content/11/1/e002116.full |
Similar Items
-
Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2023-03-01) -
Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2022-04-01) -
Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation
by: Alex J. Chang, MD, et al.
Published: (2024-03-01) -
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Leslie A. Spikes, et al.
Published: (2022-04-01) -
Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)